Valerio Therapeutics opts for strategic refocusing

On February 3, 2025, Valerio Therapeutics announced the termination of all clinical trials and related activities, including the VIO-01 trial. This decision was made by the Board of Directors to address the Company’s financing challenges. The remaining funds will cover targeted activities for the next three months. In parallel, the Company is seeking to secure a twelve-month financial trajectory through discussions with its stakeholders.

The completion of clinical trials will allow Valerio to focus on early-stage drug development, efficiently utilizing available capital. The company will exit its oncology business and close its office in Lexington, MA, to refocus on its single-chain antibody platform.

Julien Miara, CEO, stressed the importance of this decision to strengthen the company's financial position and focus on early-stage research capabilities while preserving the financial flexibility needed for future innovations.